COVID-19 Vaccination Effectiveness in the General Population of an Italian Province: Two Years of Follow-Up

Author:

Rosso Annalisa1ORCID,Flacco Maria Elena1,Soldato Graziella2,Di Martino Giuseppe2ORCID,Acuti Martellucci Cecilia1ORCID,Carota Roberto2,De Benedictis Marco2,Di Marco Graziano2,Di Luzio Rossano2,Fiore Matteo3ORCID,Caponetti Antonio2,Manzoli Lamberto3ORCID

Affiliation:

1. Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy

2. Local Health Unit of Pescara, 65124 Pescara, Italy

3. Department of Medical and Surgical Sciences, University of Bologna, 40100 Bologna, Italy

Abstract

We carried out a cohort study on the overall population of the province of Pescara, Italy, to assess the real-world effectiveness of SARS-CoV-2 vaccination against infection, severe, or lethal COVID-19, two years after the start of the vaccination campaign. We included all the resident or domiciled subjects, and extracted the official demographic, vaccination, COVID-19, hospital and co-pay exemption datasets from 1 January 2021, up to 15 February 2023. Cox proportional hazards analyses were adjusted for gender, age, diabetes, hypertension, COPD, major cardio- and cerebrovascular events, cancer, and kidney diseases. Throughout the follow-up (466 days on average), 186,676 subjects received greater than or equal to three vaccine doses (of ChAdOx1 nCoV-19, BNT162b2, mRNA-1273, NVX-CoV2373, or JNJ-78436735), 47,610 two doses, 11,452 one dose, and 44,989 none. Overall, 40.4% of subjects were infected with SARS-CoV-2. Of them, 2.74% had severe or lethal (1.30%) COVID-19. As compared to the unvaccinated, the individuals who received greater than or equal to one booster dose showed a ≥85% lower risk of severe or lethal COVID-19. A massive impact of vaccination was found among the elderly: 22.0% of the unvaccinated, infected individuals died, as opposed to less than 3% of those who received greater than or equal to three vaccine doses. No protection against infection was observed, although this finding was certainly influenced by the Italian restriction policies to control the pandemic. Importantly, during the Omicron predominance period, only the group who received at least a booster dose showed a reduced risk of COVID-19-related death.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference74 articles.

1. World Health Organization [WHO] (2023, July 05). Director-General’s Opening Remarks at the Media Briefing—5 May 2023. Available online: https://www.who.int/news-room/speeches/item/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023.

2. Efficacy and safety of COVID-19 vaccines;Grana;Cochrane Database Syst. Rev.,2022

3. Ratajczak, P., Banach, Z., Kopciuch, D., Paczkowska, A., Zaprutko, T., Krawczyk, J., Maciuszek-Bartkowska, B., and Kus, K. (2023). Tozinameran (Pfizer, BioNTech) and Elasomeran (Moderna) Efficacy in COVID-19—A Systematic Review of Randomised Controlled Trial Studies. Healthcare, 11.

4. Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis;Zheng;Int. J. Infect. Dis.,2022

5. Xu, W., Ren, W., Wu, T., Wang, Q., Luo, M., Yi, Y., and Li, J. (2023). Real-World Safety of COVID-19 mRNA Vaccines: A Systematic Review and Meta-Analysis. Vaccines, 11.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3